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Abstract
During aging, glutathione (GSH) content declines and the immune system undergoes 
a deficiency in the induction of Th1 response. Reduced secretion of Th1 cytokines, 
which is associated with GSH depletion, could weaken the host defenses against viral 
infections. We first evaluated the concentration of GSH and cysteine in organs of old 
mice; then, the effect of the administration of the N‐butanoyl GSH derivative (GSH‐
C4) on the response of aged mice infected with influenza A PR8/H1N1 virus was 
studied through the determination of GSH concentration in organs, lung viral titer, 
IgA and IgG1/IgG2a production, and Th1/Th2 cytokine profile. Old mice had lower 
GSH than young mice in organs. Also the gene expression of endoplasmic reticulum 
(ER) stress markers involved in GSH metabolism and folding of proteins, that is, 
Nrf2 and PDI, was reduced. Following infection, GSH content remained low and 
neither infection nor GSH‐C4 treatment affected Nrf2 expression. In contrast, PDI 
expression was upregulated during infection and appeared counterbalanced by GSH‐
C4. Moreover, the treatment with GSH‐C4 increased GSH content in organs, reduced 
viral replication and induced a predominant Th1 response. In conclusion, GSH‐C4 
treatment could be used in the elderly to contrast influenza virus infection by induc-
ing immune response, in particular the Th1 profile.
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1 |  INTRODUCTION
Influenza represents a global concern and a challenge for 
public health systems because of high rates of hospitaliza-
tion and deaths every year. The infection leads to self‐limit-
ing upper respiratory tract disease that resolves in few days, 
but unfortunately some individuals develop a fatal infection. 
Several factors influence the outcome of the infection among 
which the interplay between virus and host cell response 
plays a major role. The risk of influenza‐associated death is 
higher among elderly (persons aged >65 years).1
The aged immune system is characterized by an imbalance in 
the Th1/Th2 response and the lack of an efficient Th1 response 
puts the elderly at risk to exacerbation of the disease state.1
The aging process is accompanied by complex age‐related 
changes that affect the cell redox homeostasis, the immunity 
and the host defenses against viral infections. In particular, old 
individuals are characterized by chronic oxidative stress and 
low‐grade inflammation, referred to as “inflamm‐aging,” re-
sponsible for a blunted immune response, thus increasing the 
susceptibility of this population to infections and predisposing 
them to a reduced response to vaccination.2 Age‐related decline 
in the intracellular content of the tripeptide glutathione (GSH) 
has been observed in various cells and tissues.3 GSH depletion 
impairs the ability of macrophages to process antigens and se-
crete interleukin (IL)‐12 leading to the polarization toward Th2 
response patterns; on the contrary, high GSH content favors 
the Th1 response.4 IL‐12 is produced by macrophages infiltrat-
ing the influenza virus infected‐epithelium as the first response 
cytokine, and its production at the site of infection may direct 
an early immune defense to alleviate the severity of infection.5 
Unfortunately, several macrophage functions are compro-
mised with age, including cytokine and chemokine produc-
tion.6 Reduced age‐associated IL‐12 production may be partly 
attributable to the decrease in GSH content within the aging 
macrophage.6 Therefore, restoring of GSH content in macro-
phages may be useful for enhancing the immune response and 
stimulating Th1 immunity during aging.7 Fraternale et al have 
reported that the N‐butanoyl GSH derivative (GSH‐C4), a mol-
ecule able to enter cells more easily than GSH, can shift the 
immune response toward Th1 type in different immunization 
models by modulating IL‐12 secretion.8,9
Intracellular redox state plays also a pivotal role in regu-
lating the life‐cycle of influenza virus and a depletion of GSH 
was observed in infected cells.10-13 Counteracting virus‐in-
duced oxidant conditions of infected cells by GSH‐C4 sig-
nificantly inhibits influenza virus replication both in vitro and 
in vivo. In particular, GSH‐C4 interferes with the maturation 
process of viral hemagglutinin (HA) by increasing the re-
duced form of host‐cell protein disulfide isomerase (PDI).12
Therefore, although the antiviral activity of GSH‐C4 
against influenza has been demonstrated on young mice,12 to 
date no information is available about its potential role as an-
tiviral and/or immunomodulatory agent in aged mice infected 
with influenza virus. On these bases, the main aim of this 
study was to investigate whether GSH‐C4 treatment of influ-
enza A virus infected aged mice was able to affect viral rep-
lication and/or induce antiviral Th1 type immune response.
2 |  MATERIALS AND METHODS
In accordance with national law, the experiments described 
in this manuscript were approved by the Italian Ministry of 
Health. BALB/c mice (15‐month‐old and 8‐week‐old, Harlan 
Laboratories) were housed and studied under Institutional 
Animal Care and Use Committee‐approved protocols.
All animals received humane treatment, and every ef-
fort was made to minimize their suffering. Unless otherwise 
stated, all commercial products cited were used in accordance 
with the manufacturers’ instructions.
2.1 | Infection and GSH‐C4 
treatment of mice
Fifteen‐month‐old mice that had been lightly anesthetized by 
isofluorane inhalation were intranasally inoculated with 0.5 
Plaque Forming Unit (PFU)/mouse of a mouse‐adapted strain 
of influenza A/Puerto Rico/8/34 (H1N1; PR8) (infected ani-
mals) diluted in 50 µL of sterile phosphate buffered saline 
(PBS). The day of infection, mice were randomly assigned to 
treatment groups: a group was intraperitoneally (ip) treated 
with GSH‐C4 (7.4 mg in 100 µL of 0.9% NaCl, ~370 mg/Kg) 
twice to each animal, 1 hour before and immediately after 
infection. Then, mice were treated with GSH‐C4 once a day 
for the next 7 days (I + GSH‐C4). The other group was ip 
treated with 100 µL of 0.9% NaCl (I + Placebo). As control 
of infection, two groups were inoculated with 50 µL of PBS 
(mock‐infected mice) or treated with GSH‐C4 as described 
above. Each animal was weighed and rectal temperature was 
measured. At the end of the experiments, the mice were eu-
thanized with an overdose of tiletamine/zolazepam (800 mg/
kg body weight, bw) and xylazine (100 mg/kg bw).
2.2 | Determination of total IgA content and 
cytokine production in Bronchoalveolar lavage 
fluid (BALF)
At day 8 post infection (pi), a sterile 23‐gauge catheter was 
inserted into the exposed tracheal lumen of euthanized mice. 
Two instillations of sterile PBS (0.8 mL) containing protease 
inhibitors (Sigma‐Aldrich, Milan, Italy) were injected through 
the catheter and aspirated as described elsewhere.13 The BALF 
samples were centrifuged at 1000× g for 15 minutes at +4°C 
and the supernatant stored at −80°C prior to analysis.
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Total IgA antibodies, Th1 (IL‐2, IL‐12, IFN‐γ) and Th2 cy-
tokines (IL‐4, IL‐5, IL‐10) concentrations were determined in 
BALF sample obtained from mock‐infected or infected mice, 
by a multiplex assay. Plates were read on a Bio‐Plex MAGPIX 
instrument (Bio‐Rad Laboratories, Inc, Hercules, CA). The IgA 
concentrations (expressed as nanograms per milliliter) and in-
terleukin concentrations (expressed as picograms per milliliter) 
were calculated by the use of a standard curve and software pro-
vided by the manufacturer (Bio‐Plex manager software, v.6.1). 
All standards and samples were run in duplicate.
2.3 | IgG1 and IgG2a determination 
in plasma
At day 8 pi, blood was withdrawn from retro‐orbital cavity 
of mock‐infected or infected mice and IgG subtypes were de-
termined using an ELISA technique. Polystyrene microtiter 
96‐well plates (Nunc‐Immuno™ MicroWell™ plates, Sigma 
Aldrich, United States) were coated with a solution of 2.5 µg/
mL goat anti‐mouse IgG (IgG1 or IgG2a) (Bio‐Rad, Richmond, 
CA) in 0.135 mol/L NaCl pH 7.2 and incubated at 37°C over-
night. The plates were washed four times with 0.1% Tween 20 
in 10 mmol/L NaH2PO4, 154 mmol/L NaCl, pH 7.0 (TPBS) 
and blocked with 5% bovine serum albumin (BSA) in PBS for 
1 hour at 37°C. After four washings in TPBS, serial dilutions 
of murine plasma in 50 mmol/L sodium borate, pH 8.5, were 
added and incubated for 1 hour at 37°C. After four washings 
in TPBS, 100 µL of goat anti‐mouse IgG‐horseradish peroxi-
dase (HRP) conjugate (Bio‐Rad), diluted 1:1000 in PBS, were 
added. After incubation for 1 hour at 37°C, serum IgG subtypes 
were determined using a color development solution containing 
2.2 mmol/L o‐phenylenediamine. Absorbance was measured at 
492 nm on a Model 2550 enzyme immunoassay (EIA) reader.
2.4 | Assay of viral titers
A portion of lung was removed, weighed, frozen, and stored 
at −80°C. Total RNA was extracted from thawed lungs that 
had been homogenized in TRI Reagent (Sigma‐Aldrich, 
Milan, Italy) (1 mL/75 mg of tissue) with a Polytron homoge-
nizer. The RNA pellet was washed with 1 mL of 75% ethanol 
(7500× g for 5 minutes at +4°C) and air‐dried for 30 min-
utes. Diethylpyrocarbonate water (100 μL) was added, and 
tube was heated to 55°C for 15 minutes to facilitate dissolu-
tion. The isolated RNA was treated with DNase I (Invitrogen, 
Life Technologies, Monza, Italy), and its quality and quantity 
were verified spectrophometrically (Pearl Nanophotometer, 
IMPLEN, Munich, Germany). The number of viral M1 RNA 
copies was determined by quantitative real time RT‐PCR 
using the One Step Influenza A/B r‐gene and Quanti FluA 
kits (BioMérieux, Florence, Italy).
2.5 | Quantification of GSH and cysteine 
in organs
GSH and cysteine in the spleen, lymph nodes, lungs, pan-
creas, and brain of BALB/c mice were quantified following 
a HPLC method validated according to US and European 
standards14 and applied for determination of the thiol species 
in several mouse organs.15
2.6 | NRF2 and PDI expression profile 
in lungs
Total RNA was isolated as described above according to 
the manufacturer's instructions. The cDNA was synthesized 
using the RT2 first strand cDNA synthesis kit (Qiagen) from 
0.8 µg total RNA (n = 3 per each condition). The qPCR was 
performed using the primer pairs listed in Table 1. The re-
actions were performed in duplicate or triplicate in a final 
volume of 20 µL, using RT2 SYBR® Green ROX FAST 
Mastermix (Qiagen), 200 nmol/L primers, in a RotorGene 
6000 instrument (Corbett life science, Sydney, Australia). 
The amplification conditions were: 95°C for 10 minutes, 40 
cycles at 95°C for 10 seconds and 60°C for 50 seconds. A du-
plicate non‐template control was included in each PCR run. 
At the end of each run, a melting curve analysis from 60°C to 
95°C was performed to ensure the absence of primer dimers 
or non‐specific products. Relative mRNA expression anal-
ysis was calculated using the web‐based RT2 Profiler PCR 
Array data analysis software version 3.5 (SABiosciences), 
using GAPDH as a reference gene and mock‐infected mice 
as calibrator.
2.7 | Statistical analyses
Statistical significance was evaluated using GraphPad 
Prism™ software version 6.0. Test details of each experiment 
are described in the figure legends. P values <0.05 were con-
sidered significant.
T A B L E  1  Primer pairs used for NRF2 and PDI gene expression
Gene name Accession number Primer F (5′‐3′) Primer R (5′‐3′)
Nfe2l2 (NRF2) NM_010902 CACATTCCCAAACAAGATGCCT TATCCAGGGCAAGCGACTCA
P4hb (PDI) NM_011032 GATCAAGCCCCACCTGATGA ACCTCTTCAAAGTTCGCCCC
Gapdh NM_001289726 TGCCCCCATGTTTGTGATG TGTGGTCATGAGCCCTTCC
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3 |  RESULTS
3.1 | Old mice contain low quantity of GSH 
and cysteine in different organs except for the 
brain
Aging is characterized by a progressive decline in GSH con-
centration in humans and rodents, as well as in senescent 
cells in culture.3 Therefore, at first we evaluated the basal 
concentrations of GSH and cysteine in spleen, lymph nodes, 
lungs, pancreas, and brain of aged and young mice. As re-
ported in Figure 1, the content of thiol species of aged mice 
was lower in all organs. Specifically, statistically significant 
differences in GSH content were recorded in lymph nodes, 
lungs, and pancreas. Evident reductions, although not signifi-
cant, were found in the spleen, while no changes were found 
in the brain (Figure 1A). Quantification of cysteine was more 
difficult because of the previously reported low content of 
this aminoacid in BALB/c mice14; however, we observed 
in pancreas of old mice, where the highest concentration of 
cysteine was measured, a marked decrease in the aminoacid 
(P = 0.06) (Figure 1B).
3.2 | Treatment with GSH‐C4 inhibits viral 
yields in the lungs of infected mice
We have previously demonstrated that treatment with 
GSH‐C4 strongly inhibits influenza virus replication in 6‐
week‐old mice.12 In this paper, the antiviral effect of the 
GSH derivative in 15‐month‐old mice was evaluated. For 
all the duration of the treatments, animals were daily moni-
tored for survival, clinical signs of infection, body weight, 
and body temperature. At selected time, lungs were used 
for measuring viral titers. According with the results ob-
tained in the young mice,12 both groups showed signs of 
infection starting from day 4 pi, but Placebo‐treated mice 
were more affected than GSH‐C4‐treated ones. Indeed, loss 
of body weight (Figure 2A) and decrease in temperature 
(Figure 2B) were more pronounced in the Placebo‐treated 
mice, especially late in infection. Furthermore, on day 8 
pi, viral M1 RNA copies were significantly reduced in the 
GSH‐C4‐treated group (Figure 2C).
3.3 | Treatment with GSH‐C4 increases 
GSH concentration in organs of infected mice
Influenza virus causes redox changes in infected cells and 
GSH depletion favors virus replication10-13,16,17; hence, at 
day 8 pi we investigated whether infection and/or GSH‐C4 
treatment modified GSH content in spleen, lymph nodes, 
lungs, pancreas, and brain of old mice. Surprisingly, GSH 
content was increased in all the organs of infected mice, 
except in the brain (Figure 3). In details, statistically sig-
nificant raises were observed in lymph nodes and pan-
creas while evident increases, although not statistically 
relevant, were recorded in lungs and spleen. Interestingly, 
GSH‐C4 treatment further increased GSH level in the 
lymph nodes and lungs (P = 0.06 and 0.03 vs I + Placebo, 
respectively) while it had no significant effect on the other 
organs (Figure 3).
3.4 | Treatment with GSH‐C4 reduces the 
expression of PDI but not that of Nrf2 in 
lungs of infected mice
Activation of nuclear factor‐erythroid‐2 related factor 2 
(Nrf2) may be deregulated during the aging process.18 It is 
also known that Nrf2 controls GSH production and regen-
eration,19 and that a modified expression of Nrf2 can alter 
influenza virus entry and subsequent replication.20 Having 
F I G U R E  1  Reduced glutathione (GSH) and cysteine content in 
organs of young and aged mice. GSH (A) and cysteine (B) contents 
were quantified in the spleen, lymph nodes, lungs, pancreas and brain 
of young (8‐week‐old) and aged (15‐month‐old) mice through HPLC 
according to the procedure described in the Materials and Methods 
section. Values represent the mean ± SD of three mice, each performed 
in duplicate (n = 6) and are expressed as µmoles/g organ. Unpaired 
data were analyzed with the Student's t test with Welch correction 
*P < 0.05; **P = 0.005; vs young mice; a: the value is referred to one 
mouse; ND: not detectable
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found very low quantity of GSH in the lungs of old mice 
(Figure 1A), we first investigated Nrf2 expression in lung 
homogenate of old and young mice, then how it was influ-
enced by both infection and GSH‐C4 treatment in old mice. 
Interestingly, as shown in Figure 4A, Nrf2 expression was 
significantly lower in old mice respect to the young ones. 
With regard to infected mice, neither viral infection nor 
GSH‐C4 treatment significantly affected Nrf2 expression 
(Figure 4B).
Next, we turned our attention on PDI, a chaperone neces-
sary for proper protein folding, and generally impaired during 
the aging process.21 Previously, PDI has been reported to me-
diate infection of enveloped viruses22 and, in the NCI‐H292 
lung cells infected with influenza virus, its expression was 
increased.12 Furthermore, GSH‐C4 treatment, by altering the 
redox state of both PDI and HA proteins, inhibited viral replica-
tion.12 Here, we studied the gene expression of PDI in lung ho-
mogenate of old and young mice (Figure 4C), and evaluated the 
effect of infection and GSH‐C4 treatment on its transcription in 
old mice (Figure 4D). As shown in Figure 4C, the basal expres-
sion of PDI was significantly reduced in old mice respect to the 
young. Accordingly to previous results,12 the influenza virus 
induced a significant up‐regulation of PDI expression, which 
appeared significantly counterbalanced by GSH‐C4 treatment 
(Figure 4D).
3.5 | Treatment with GSH‐C4 induces the 
production of IgA and IgG in infected mice
The immune system undergoes dramatic age‐associated re-
modeling, including deficiency in the induction of specific 
Th1 cells. In order to assess the possible immunomodulatory 
effect of GSH‐C4 in infected aged mice, IgA titer was meas-
ured in BALF collected from mock‐infected (Ctr) and infected 
mice. As shown in Figure 5, influenza virus caused a sig-
nificant increase in the IgA concentration (***P = 0.0002). 
Although the treatment with GSH‐C4 seemed to partially 
F I G U R E  2  Antiviral effect of GSH‐C4 in aged mice. Fifteen‐
month‐old mice were infected with a mouse‐adapted strain of 
influenza A/Puerto Rico/8/34 (H1N1; PR8) and treated with Placebo 
(I + Placebo) or GSH‐C4 (I + GSH‐C4) as described in the Materials 
and Methods section. The graphs represent the percentages of body 
weight (A) and body temperature (B) vs time 0 recorded in mice 
during treatment with GSH‐C4 (squares) or Placebo (circles). At day 
8 pi, viral M1 RNA copies were measured in lungs (C) by quantitative 
Real Time (qRT‐PCR) as described in the Materials and Methods 
section. Results are the mean ± SD of five mice, each run in duplicate 
(n = 10). (A) and (B): Multiple t test followed by Holm‐Sidak 
method: **P = 0.003; ***P = 0.0004 vs I + Placebo; (C): Unpaired 
data were analyzed with the Student's t test with Welch correction: 
**P = 0.003
F I G U R E  3  Reduced glutathione (GSH) content in the organs 
of infected aged mice. Fifteen‐month‐old mice were infected with a 
mouse‐adapted strain of influenza A/Puerto Rico/8/34 (H1N1; PR8) 
and treated with Placebo (I + Placebo) or GSH‐C4 (I + GSH‐C4) as 
described in the Materials and Methods section. At day 8 pi, GSH 
level was quantified in the spleen, lymph nodes, pancreas, and brain 
as described in the Materials and Methods section. Values represent 
the mean ± SD of three mice each performed in duplicate (n = 6). 
Unpaired data were analyzed with the Student's t test with Welch 
correction: *P < 0.05, **P = 0.002 vs Ctr (mock‐infected mice); 
§P < 0.05 vs I + Placebo
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reduce IgA content with respect to Placebo‐infected mice, 
the ratio IgA titer/viral copies produced in GSH‐C4‐treated 
mice was significantly higher compared with Placebo‐treated 
mice (Figure 5B).
In mice, high concentrations of IgG1 are associated with 
a Th2‐type immune response, while high IgG2a titers are 
indicative of a Th1 response.23 For this reason, the ability 
of GSH‐C4 to modulate the Th1/Th2 response was investi-
gated by measuring IgG1 and IgG2a titer in plasma of in-
fected mice. We found that viral infection induced both IgG1 
and IgG2a production (Figure 6A,B, respectively) and that 
GSH‐C4 treatment increased both IgG subtypes, although 
IgG2a expression reached a concentration that was statisti-
cally higher than Placebo treatment (Figure 6B).
3.6 | Treatment with GSH‐C4 induces a 
predominant Th1 cytokine profile
Finally, to evaluate the capacity of GSH‐C4 to shift the im-
mune response toward Th1 type in old infected mice, the 
production of Th1 (IL‐2, IL‐12, IFN‐γ) and Th2 (IL‐4, IL‐5, 
IL‐10) cytokines was investigated. Eight days after infec-
tion, quantitative analysis of cytokines performed in BALF 
of infected mice, revealed that treatment with GSH‐C4 pre-
dominantly influenced differentiation toward the Th1 pheno-
type. In fact, we found that GSH‐C4 treatment enhanced the 
production of all the cytokines except IL‐10, but only Th1 
cytokine production, and in particular IL‐2 and IL‐12, were 
significantly higher in GSH‐C4‐treated mice compared with 
those measured in mice receiving Placebo, shifting Th1/Th2 
response in favor of Th1 (Figure 7).
4 |  DISCUSSION
In this study, we demonstrate that basal GSH content is lower 
in several organs of aged compared with young mice. Since 
human influenza strains replicate almost exclusively in su-
perficial cells of the respiratory tract,24 we chose to evaluate 
most of parameters only in lungs isolated from infected mice. 
The significant decrease in mRNA expression of Nrf2, the 
transcription factor that controls the expression of the glu-
tamate cysteine ligase, the rate limiting enzyme of GSH de 
novo synthesis,19 could explain the observed GSH low con-
centration in the lungs of old mice. Differently from what 
reported in previous papers, where influenza virus infection 
was associated with the depletion of GSH,10-12 in this study 
an increase in the tripeptide in old infected animals was ob-
served. Indeed, old mice did not possess physiological GSH 
concentrations at the time of infection (Figure 1A). Thus, we 
hypothesize that, following infection of old animals, different 
intracellular pathways can be activated depending on their 
intracellular redox state. Further studies are in progress to 
unravel this concern.
F I G U R E  4  Expression of NRF2 and PDI genes in lung homogenate of young and aged mice and of infected aged mice 15‐month‐old mice 
were infected with a mouse‐adapted strain of influenza A/Puerto Rico/8/34 (H1N1; PR8) and treated with Placebo (I + Placebo) or GSH‐C4 
(I + GSH‐C4) as described in the Materials and Methods section. Lung homogenate was obtained at day 8 pi. The fold change respect to Young 
(A and C) or to Ctr (mock‐infected mice) (B and D) was calculated from three biological replicates using 2−ΔΔCt method with normalization of 
the raw data to the reference gene GAPDH. Data analysis was performed using the web‐based RT2 Profiler PCR Array data analysis software 
(SABiosciences). The error bars represent 95% confidence intervals. Unpaired t test with Welch's correction *P < 0.05, **P = 0.0094
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Regarding the effect of GSH‐C4, the peritoneal administra-
tion of this molecule in old mice increased GSH concentration 
in lymph nodes and lungs of mice. On the contrary, no GSH 
raise was measured in the organs where GSH concentration 
was not depleted, suggesting that it may have different effects 
on the GSH content and the redox‐mediated regulation of in-
tracellular signaling depending on the redox status of the cell.
Regarding the mechanism of action through which GSH‐
C4 could increase GSH content, we hypothesize that the ec-
toenzyme λ‐glutamyl transpeptidase (λGT) can catalyze the 
transfer of the λ‐glutamyl moiety from GSH‐C4 onto an ac-
ceptor molecule, thereby generating the CysGly conjugate.25 
CysGly may be hydrolyzed by ectopeptidases to cysteine 
and glycine, which can be used for cellular GSH synthesis.19 
Hence, in a GSH‐depleted cell, GSH‐C4 treatment can in-
crease intracellular thiol content in the form of GSH‐C4 and 
by raising GSH level.
Previously we have demonstrated that influenza virus 
infection enhances expression of PDI and that GSH‐C4 
treatment reduces the enzyme's ability to fold correctly HA 
by interfering with the oxidation state of PDI.12 The data 
reported in this paper suggest that by interfering with ex-
pression and likely redox state of PDI, GSH‐C4 can inhibit 
influenza A virus replication also in old mice.
Actually, in this paper we show that the inhibitory effect 
of GSH‐C4 treatment on influenza virus infection in old mice 
is more complex than merely inhibiting viral replication; in 
fact, it influenced the host immune response by increasing 
both IgA in BALF as well as IgG1 and IgG2a in plasma. 
This aspect is important since antibodies possess neutraliz-
ing properties, but IgG2a can stimulate antibody‐dependent 
cell‐mediated cytotoxicity and opsonophagocytosis by mac-
rophages, contributing to the clearance of influenza virus 
F I G U R E  5  IgA titer in BALF of infected aged mice. (A) IgA 
content was measured in BALF obtained from Ctr (mock‐infected 
mice) and infected mice treated with Placebo (I + Placebo) or GSH‐C4 
(I + GSH‐C4) at day 8 pi. Mouse infection and the methods used for 
determination of IgA level are described in the Materials and Methods 
section. Values represent the mean ± SD of 5 mice, each run in 
duplicate (n = 10). Unpaired t test with Welch's correction: *P < 0.05; 
***P = 0.0002 vs Ctr. (B) Ratio of IgA ng/viral M1 RNA copies in 
infected aged mice treated with Placebo or GSH‐C4. Unpaired t test 
with Welch's correction *P = 0.03 vs I + Placebo
F I G U R E  6  Plasma IgG1 and IgG2a titers in infected aged 
mice. Fifteen‐month‐old mice were infected with a mouse‐adapted 
strain of influenza A/Puerto Rico/8/34 (H1N1; PR8) and treated with 
Placebo (I + Placebo) or GSH‐C4 (I + GSH‐C4) as described in the 
Materials and Methods section. At day 8 pi, IgG1 (A) and IgG2a 
(B) were determined by ELISA as described in the Materials and 
Methods section. Antibody titers are reported as optical density (OD) 
of the 1/32000 dilution. Values represent the mean ± SD of five mice, 
each run in duplicate (n = 10). Unpaired data were analyzed with 
the Student's t test with Welch correction: *P = 0.01, **P < 0.005, 
***P < 0.0005
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from infected hosts.26,27 Moreover, stimulation of IgG2a an-
tibodies has been associated with increased efficacy of influ-
enza vaccination27; for this reason, the finding that GSH‐C4 
treatment can increase both IgG subtypes, and in particular 
IgG2a, deserves further studies to investigate the use of GSH‐
C4 to enhance influenza vaccine‐specific IgG responses par-
ticularly in the elderly.
In addition, IgA induction in the mucosal tissue by GSH‐
C4 treatment is another important point to consider given the 
fact that the main entrance for many pathogens such as influ-
enza is the mucosal tissues. IgA can neutralize influenza vi-
ruses at the mucosal interface, even before they actually enter 
the host by crossing the mucosal barrier, thus existing IgA 
is the first line of defense upon reinfection or infection after 
vaccination. Moreover, IgA can effectively clear the virus in 
infected epithelial cells.28
Furthermore, GSH‐C4 treatment can influence the pro-
duction of Th1/Th2 cytokines. The increase in IL‐2 con-
centration is particularly interesting considering that the 
production of this cytokine declines with age and that it is 
lower in old mice infected with influenza virus.29 Moreover, 
we establish a link between the increased GSH content in 
the lungs and elevated production of IL‐12 in the BALF 
of influenza virus infected old mice treated with GSH‐C4. 
Hence, in agreement with previous works showing that GSH 
concentration influence IL‐12 production and Th response 
patterns,4,7-9 we can conclude that in old mice infected with 
influenza virus, Th1/Th2 cytokine production can be also in-
fluenced by the redox state. In summary, GSH‐C4 treatment, 
by enhancing intracellular GSH content, elicited strong IgA 
and cellular immune responses that resulted in reduced lung 
virus titers in old mice (Table 2).
In our study, the senescent mouse model allowed us to 
obtain important insight to knowledge of the role of GSH 
in the immune defenses to invading pathogens. The murine 
model has been widely employed as a model for the inves-
tigation of aging, as well as immune response to influenza 
virus infection.30,31 Recently, comparative studies on the im-
mune responses to IAV infection between aged and young 
mice highlighted the relevance of mice as model for human 
aging and outcomes to IAV infection.33,34
So, as widely reported,4,7-9,15 the results described in this 
paper, reinforce the conclusion that GSH exerts an important 
role in antiviral immunity, not simply as ROS scavenger, but 
F I G U R E  7  Th1 and Th2 cytokine profile in infected aged mice. Production of Th2 cytokines (IL‐4, IL‐5, IL‐10) (above) and of Th1 
cytokines (IL‐2, IL‐12, IFN‐γ) (below) in BALF obtained from infected mice either treated with Placebo (I + Placebo) or GSH‐C4 (I + GSH‐C4) 
at day 8 pi. Cytokine assays were performed as described in the Materials and Methods section. Values, reported as ratio of IL pg/viral copies, 
represent the mean ± SD of five mice, each run in duplicate (n = 10). Unpaired data were analyzed with the Student's t test with Welch correction: 
**P = 0.0098, ***P = 0.0003 vs I + Placebo
T A B L E  2  Effect of GSH‐C4 treatment on old mice infected with 
PR8
 GSH‐C4 treatment
GSH concentration in lymph nodes and 
lungs
>
Th1/Th2 ratio in BALF >
IL‐2 and IL‐12 pg/viral copies in BALF >
IgA titer/viral copies in BALF >
IgG1 and IgG2a in plasma >
Viral M1 RNA copies in lungs <
Body weight and body temperature loss <
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by influencing the antiviral GSH‐dependent signaling path-
ways impaired by the virus. Therefore, the use of a molecule 
as GSH‐C4, equipped with both antiviral and immunomodu-
latory activity, may constitute a goal in the fighting influenza 
virus infection in aged people. The application of GSH‐C4 
as vaccine adjuvant/immunomodulator in the prevention and 
treatment of influenza infection could be further explored 
in particular in elderly people where an unbalanced Th1/
Th2 immune response is one of the reasons for the decline 
in function of the immune system leading to the failure of the 
vaccines commonly used.
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